TY - JOUR
T1 - Topically Applied Imiquimod Inhibits Vascular Tumor Growth In Vivo
AU - Sidbury, Robert
AU - Neuschler, Nicole
AU - Neuschler, Erin
AU - Sun, Ping
AU - Wang, Xiao Qi
AU - Miller, Richard
AU - Tomai, Mark
AU - Puscasiu, Elena
AU - Gugneja, Sajiv
AU - Paller, Amy S.
N1 - Funding Information:
These investigator-initiated studies were funded by grants from the March of Dimes, the Dermatology Foundation, the Unilever Endowment and the Chicago Dermatological Society. The imiquimod cream and vehicle control base were provided by 3M Pharmaceuticals.
PY - 2003/11
Y1 - 2003/11
N2 - Vascular tumors occur in approximately 10% of all infants and may be associated with significant morbidity. Available therapies for vascular tumors, such as systemic corticosteroids, vincristine, and interferon-α, may cause toxicity, limiting their use to complicated cases. Using a mouse hemangioendothelioma model, we investigated the efficacy and mechanism of action of imiquimod, a topically applied inducer of cytokines. Application of imiquimod cream, whether initiated at the time of cell inoculation or when tumors became visible, significantly decreased tumor growth and increased animal survival in comparison with control mice. Imiquimod-treated tumors showed decreased tumor cell proliferation, increased tumor apoptosis, and increased expression of tissue inhibitor of matrix metalloproteinase-1 with decreased activity of matrix metalloproteinase-9. The demonstration that local application of imiquimod inhibits vascular tumor enlargement in the mouse vascular tumor model suggests a novel, less toxic means of treating infantile hemangioendotheliomas and perhaps other cutaneous vascular tumors.
AB - Vascular tumors occur in approximately 10% of all infants and may be associated with significant morbidity. Available therapies for vascular tumors, such as systemic corticosteroids, vincristine, and interferon-α, may cause toxicity, limiting their use to complicated cases. Using a mouse hemangioendothelioma model, we investigated the efficacy and mechanism of action of imiquimod, a topically applied inducer of cytokines. Application of imiquimod cream, whether initiated at the time of cell inoculation or when tumors became visible, significantly decreased tumor growth and increased animal survival in comparison with control mice. Imiquimod-treated tumors showed decreased tumor cell proliferation, increased tumor apoptosis, and increased expression of tissue inhibitor of matrix metalloproteinase-1 with decreased activity of matrix metalloproteinase-9. The demonstration that local application of imiquimod inhibits vascular tumor enlargement in the mouse vascular tumor model suggests a novel, less toxic means of treating infantile hemangioendotheliomas and perhaps other cutaneous vascular tumors.
KW - Cytokines
KW - Hemangioendothelioma
KW - Neoplasm
UR - http://www.scopus.com/inward/record.url?scp=10744223783&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10744223783&partnerID=8YFLogxK
U2 - 10.1046/j.1523-1747.2003.12521.x
DO - 10.1046/j.1523-1747.2003.12521.x
M3 - Article
C2 - 14708627
AN - SCOPUS:10744223783
VL - 121
SP - 1205
EP - 1209
JO - Journal of Investigative Dermatology
JF - Journal of Investigative Dermatology
SN - 0022-202X
IS - 5
ER -